Skip to main content
SpringerLink
Log in

Indapamide Sustained Release

A Review of its Use in the Treatment of Hypertension

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

A low-dose sustained-release (SR) formulation of the thiazide-type diuretic indapamide, indapamide SR (Natrilix® SR), retains the antihypertensive activity of the immediate-release (IR) formulation, with a smoother pharmacokinetic profile.

In well controlled 12- to 52-week clinical trials, indapamide SR 1.5 mg/day was well tolerated and reduced blood pressure as effectively as therapeutic dosages of amlodipine, candesartan, enalapril, hydrochlorothiazide or indapamide IR. Indapamide SR was also more effective than enalapril in reducing left ventricular hypertrophy (LVH), and similar reductions in renal end-organ damage, assessed by microalbuminuria, were seen with indapamide SR- and enalapril-based antihypertensive strategies. Indapamide SR provides an effective option for initial antihypertensive monotherapy and a basis for multidrug antihvpertensive strategies.

Pharmacological Properties

Indapamide inhibits sodium chloride cotransport in the cortical diluting segment of the proximal distal tubule, as well as inhibiting a membrane-bound form of carbonic anhydrase.

Therapeutic dosages of indapamide have only a mild diuretic activity; the primary antihypertensive activity of low-dose indapamide appears to occur through a direct vasodilatory effect. Indapamide also reduces vascular hypertrophy and LVH in animal models of pressure overload.

Serum or plasma sodium and glucose levels in hypertensive patients were unaffected by indapamide SR monotherapy over 12 to 52 weeks; modest reductions in potassium and increases in uric acid levels have been observed.

Indapamide SR 1.5 mg/day for 7 days achieved a lower maximum blood indapamide concentration (Cmax) than indapamide IR 2.5 mg/day (58 vs 154 µg/ L) and took longer to reach Cmax (11.0 vs 0.8 hours), while total exposure (area under the concentration-time curve from time 0–24 hours corrected for dose; 726 vs 690 µg · h/L) and minimum concentration (38 vs 41 µg/L) were similar. Indapamide undergoes extensive hepatic metabolism, and elimination occurs in a biphasic manner (terminal elimination half-life 15–24 hours), mainly through renal (≈70%) and biliary (≈22%) pathways.

Therapeutic Efficacy

In well controlled clinical trials of 12–52 weeks’ duration, indapamide SR 1.5 mg/ day reduced both mean supine systolic blood pressure (SBP) and diastolic blood pressure (DBP). In patients with essential hypertension or isolated systolic hypertension, the reductions in mean supine SBP and DBP induced by indapamide SR were significantly larger than those seen with placebo, and SBP reductions were greater than those with enalapril 10 mg/day. Reductions in supine SBP and DBP with indapamide SR were similar to those with amlodipine 5 mg/day, candesartan 8 mg/day, indapamide IR 2.5 mg/day and enalapril 20 mg/day. In elderly patients (aged ≥65 years), reductions in mean supine SBP and DBP induced by indapamide SR were equivalent to those with amlodipine 5 mg/day or hydrochlorothiazide 25 mg/day.

End-organ damage was also reduced by indapamide SR. LVH was reduced in indapamide SR 1.5 mg/day but not enalapril 20 mg/day recipients after 48 weeks of therapy in patients with essential hypertension. In patients with type 2 diabetes mellitus, multidrug indapamide SR 1.5 mg/day based and enalapril 10 mg/day-based antihypertensive strategies induced similar reductions in urinary albumin: creatinine ratio and fractional albumin clearance; noninferiority was not demonstrated in the reduction of albumin excretion rate.

Tolerability

Indapamide SR 1.5 mg/day was generally well tolerated. Headache, back pain, nausea and diarrhoea were observed at relatively low rates (0.2–1.6%), and orthostatic hypotension was observed in 0.4–8.6% of recipients. Hypokalaemia (serum potassium <3.4 mmol/L) occurred in 4–11 % of indapamide SR recipients, while the incidence of moderate to severe hypokalaemia (<3.0 mmol/L) was 0–1.5%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table III
Table II
Table IV
Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. Natrilix® SR, Natrilix® LP, Natrilix® Retard, Natrilix® AP, Fludex® LP, Fludex® Retard, Fludex® SR, Fludex® 1.5mg, Tertensif® SR, Tertensif® Retard, Pretanix®. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. World Health Organization. The World Health Report 2002. Reducing risks, promoting healthy life [online]. Available from URL: http://www.who.int/whr/2002/en/index.html [Accessed 2004 Jun 13]

  2. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335(8693): 827–38

    CAS  Google Scholar 

  3. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 Mar; 18(3): 139–85

    Article  PubMed  CAS  Google Scholar 

  4. World Health Organization International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21(11): 1983–92

    Article  Google Scholar 

  5. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21(6): 1011–53

    Article  Google Scholar 

  6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 Dec; 42(6): 1206–52

    Article  PubMed  CAS  Google Scholar 

  7. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 Nov 24; 157: 2413–46

    Article  Google Scholar 

  8. Chaffman M, Heel RC, Brogden RN, et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984 Sep; 28(3): 189–235

    Article  PubMed  CAS  Google Scholar 

  9. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996 1996; 77(6): 12–16b

    Article  Google Scholar 

  10. Campbell DB, Brackman F. Cardiovascular protective properties of indapamide. Am J Cardiol 1990 May 2; 65: 11–27H

    Article  Google Scholar 

  11. Molyneaux LM, Willey KA, Yue DK. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. J Cardiovasc Pharmacol 1996 Mar; 27(3): 424–7

    Article  PubMed  CAS  Google Scholar 

  12. Carey PA, Sheridan DJ, de Cordoue A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996; 77(6): 17–19b

    Article  Google Scholar 

  13. Damien G, Huet de Barochez B, Schiavi P. Galenic development and pharmacokinetic profile of indapamide sustained release 1.5mg. Clin Pharmacokinet 1999; 37 (Suppl. 1): 13–9

    Article  PubMed  CAS  Google Scholar 

  14. Schaeffer P, Vigne P, Frelin C, et al. Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol 1990 Jul 17; 182(3): 503–8

    Article  PubMed  CAS  Google Scholar 

  15. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide: rationale for use in hypertension. Clin Pharmacokinet 1999; 37 (Suppl. 1): 7–12

    Article  PubMed  CAS  Google Scholar 

  16. Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension 1999 Apr; 33(4): 1043–8

    Article  PubMed  CAS  Google Scholar 

  17. Pruss T, Wolf PS. Preclinical studies of indapamide, a new 2-methylindoline antihypertensive diuretic. Am Heart J 1983 Jul; 106 (1 Pt 2): 208–11

    Article  PubMed  CAS  Google Scholar 

  18. Mironneau J, Savineau JP, Mironneau C. Effect of indapamide on the electromechanical properties of rat myometrium and rat portal vein. J Pharmacol Exp Ther 1986 Feb; 236(2): 519–25

    PubMed  CAS  Google Scholar 

  19. Thomas JR. A review of 10 years of experience with indapamide as an antihypertensive agent. Hypertension 1985 Nov–Dec; 7 (6 Pt 2): II152–6 1985 Nov–Dec; 7 (6 Pt 2): II152-156

    Article  PubMed  CAS  Google Scholar 

  20. Servier Laboratories Ltd. Natrilix SR [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 May 12]

  21. Calder JA. Mechanism of antihypertensive action of thiazide diuretics and related drugs: direct vascular effects. J Drug Dev 1992 Apr; 4(4): 189–98

    CAS  Google Scholar 

  22. Rendu F, Bachelot C, Molle D, et al. Indapamide inhibits human platelet aggregation in vitro: comparison with hydrochlorothiazide. J Cardiovasc Pharmacol 1993; 22 (Suppl. 6): S57–63

    PubMed  CAS  Google Scholar 

  23. Kyncl J, Oheim K, Seki T, et al. Antihypertensive action of indapamide: comparative studies in several experimental models. Arzneimittelforschung 1975 Oct; 25(10): 1491–5

    PubMed  CAS  Google Scholar 

  24. Breugnot C, Iliou JP, Privat S, et al. In vitro and ex vivo inhibition of the modification of low-density lipoprotein by indapamide. J Cardiovasc Pharmacol 1992 Sep; 20(3): 340–7

    Article  PubMed  CAS  Google Scholar 

  25. Acchiardo SR, Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J 1983 Jul; 106 (1 Pt 2): 237–44

    Article  PubMed  CAS  Google Scholar 

  26. Ganado P, Ruiz E, Del Rio M, et al. Growth inhibitory activity of indapamide on vascular smooth muscle cells. Eur J Pharmacol 2001 Sep 28; 428(1): 19–27

    Article  PubMed  CAS  Google Scholar 

  27. Chillon JM, Baumbach GL. Effects of indapamide, a thiazidelike diuretic, on structure of cerebral arterioles in hypertensive rats. Hypertension 2004 May; 43(5): 1092–7

    Article  PubMed  CAS  Google Scholar 

  28. Böcker W, Hupf H, Grimm D, et al. Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J Cardiovasc Pharmacol 2000 Oct; 36(4): 481–6

    Article  PubMed  Google Scholar 

  29. Ambrosioni E, Safar M, Degaute JP, et al. on behalf of the European study group. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertens 1998 Nov; 16(11): 1677–84

    CAS  Google Scholar 

  30. Emeriau JP, Knauf H, Pujadas JO, et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001 Feb; 19(2): 343–50

    Article  PubMed  CAS  Google Scholar 

  31. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000 Oct; 18(10): 1465–75

    Article  PubMed  CAS  Google Scholar 

  32. London GM, Schmieder R, Calvo C, et al. on behalf of the X-CELLENT study investigators. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT study. Am J Hypertens 2006 Jan; 19 (113-21)

    Google Scholar 

  33. Marre M, Garcia Puig J, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004 Aug; 22(8): 1613–22

    Article  PubMed  CAS  Google Scholar 

  34. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf 2001; 24(15): 1155–65

    Article  PubMed  CAS  Google Scholar 

  35. Leonetti G, Emeriau JP, Knauf H, et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005 Jan; 21(1): 37–46

    Article  PubMed  CAS  Google Scholar 

  36. Greenberg A. Diuretic complications. Am J Med Sci 2000 Jan; 319(1): 10–24

    Article  PubMed  CAS  Google Scholar 

  37. Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol 2000 Mar–Apr; 14: 139–46

    Article  PubMed  CAS  Google Scholar 

  38. Servier Laboratories (NZ) Ltd. Data Sheet. Natrilix SR indapamide hemihydrate 1.5 mg [online]. Available from URL: http://www.medsafe.govt.nz/Profs/Datasheet/n/NatrilixSRtab.htm [Accessed 2005 Jun 9]

  39. Caruso FS, Szabadi RR, Vukovich RA. Pharmacokinetics and clinical pharmacology of indapamide. Am Heart J 1983 Jul; 106 (1 Pt 2): 212–20

    Article  PubMed  CAS  Google Scholar 

  40. Leonetti G. Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension. Drugs 2000; 59 (Suppl. 2): 27–38

    Article  PubMed  CAS  Google Scholar 

  41. Füsgen I, Schütz D. Use of indapamide SR in elderly patients in general practice: results of a prospective study of 3034 elderly multimorbid patients [in German]. Eur J Ger 2001; 3(4): 196–200

    Google Scholar 

  42. British National Formulary. Available from URL: http://www.bnf.org [Accessed 2005 Jun 1]

  43. World Health Organization. The World Health Report 2003: shaping the future [online]. Available from URL: http://www.who.int/whr/2003 [Accessed 2005 Sep 9]

  44. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 Jun 13; 351(9118): 1755–62

    CAS  Google Scholar 

  45. Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998 Jul 18; 317(7152): 167–71

    Article  PubMed  CAS  Google Scholar 

  46. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362(9395): 1527–35

    Article  PubMed  CAS  Google Scholar 

  47. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363(9426): 2022–31

    Article  PubMed  CAS  Google Scholar 

  48. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288(23): 2981–97

    Article  Google Scholar 

  49. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000 Apr 19; 283(15): 1967–75

    Article  Google Scholar 

  50. Writing Group of the American Society of Hypertension. Medical experts redefine hypertension. Writing group urges expansion of the definition of hypertension: move paves the way for new avenues in disease management and research efforts [media release] [online]. Available from URL: http://www.ashus.org/annual_meeting/2005/press/0514057.htm [Accessed 2005 Jun 10]

  51. Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18(3): 151–64

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Dean M. Robinson & Keri Wellington

Authors
  1. Dean M. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keri Wellington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean M. Robinson.

Additional information

Various sections of the manuscript reviewed by: E. Ambrosioni, Divisione Medicina Interna, Policlinico S. Orsola, Università di Bologna, Bologna, Italy; R. Asmar, L’Institut Cardiovasculaire, Paris, France; R. Donnelly, Derby City General Hospital, University of Nottingham, Derby, England; N.M. Kaplan, University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas, USA; F.H.H. Leenen, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; G. Leonetti, Department of Cardiology, Ospedale San Luca, Milan, Italy; H.F. McIntyre, Conquest Hospital, Hastings, England; P.A. Meredith, University Department of Medicine and Therapeutics, The Western Infirmary, Glasgow, Scotland.

Data Selection

Sources: Medical literature published in any language since 1980 on indapamide SR, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘indapamide SR’ or ‘indapamide sustained release’. Searches were last updated 9 Jan 2006.

Selection: Studies in patients with hypertension who received indapamide SR. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Indapamide SR, hypertension, left ventricular hypertrophy, microalbuminuria, pharmacodynamics, pharmacokinetics, therapeutic use.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, D.M., Wellington, K. Indapamide Sustained Release. Drugs 66, 257–271 (2006). https://doi.org/10.2165/00003495-200666020-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666020-00011

Keywords

Search

Navigation